Sign in
Stories
Sensorion Advances Hearing Loss Prevention Trial
Share
AudioCure Pharma's Hearing Technology In...
BioSenic's Progress and Patent
Biotech Advancements in Hearing Loss Tre...
Gene Therapy Revolutionizes Hearing Loss...
Myonex Acquires Creapharm's Business
Perion Acquires Hivestack for DOOH Growt...
Overview
API
Sensorion, a French biotechnology company, advances its Phase 2a clinical trial for SENS-401, a compound aimed at preventing cisplatin-induced hearing loss. The study's progress and potential to improve patients' quality of life are highlighted by the company's CEO.
Ask a question
How might the successful completion of this clinical trial impact the pharmaceutical industry's approach to hearing loss prevention?
In what ways could this advancement in hearing loss prevention contribute to broader healthcare advancements and patient outcomes?
What potential challenges could arise in the widespread adoption of SENS-401, and how might they be addressed?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Sep 2023
Oct 2023
Nov 2023
Coverage